Insulin Lispro Trial "Oral Anti Diabetic Agents in the Hospital" Terminated

A Phase 4 clinical trial involving insulin lispro has been marked as terminated, according to a record dated August 31, 2026. The trial, titled "Oral Anti Diabetic Agents in the Hospital," is registered under identifier NCT04416269. The listing indicates a status of terminated for this Phase 4 study. No results, reasons for termination, or outcome data were included in the available record. Insulin lispro is an approved compound, and this update pertains specifically to the status of this individual trial registration rather than to its overall regulatory standing. Readers should note that a termination status reflects a change in the trial's conduct as recorded on clinicaltrials.gov, and does not by itself indicate any finding about safety or effectiveness. Further details on the scope of the study, including its original design and comparator agents, are not specified in this update. Those interested in tracking developments related to this registration can refer to the official clinical trial record for additional documentation as it becomes available. For general background on this compound, see the linked compound overview.